ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2323

Predictors of Mortality in Patients with Hip Fragility Fracture

Miguel Guerra1, Sara Ganhão2,3, Francisca Aguiar2,3, Georgina Terroso2, Romana Vieira1, Diana Gonçalves4, Tiago Meirinhos5, Teresa Martins-Rocha2,3, Ana Águeda3,5, Raquel Ferreira2,3, Miguel Bernardes2,3, Carlos Vaz2,3, Raquel Lucas6 and Lúcia Costa2, 1Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 2Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, 3Faculty of Medicine, Oporto University, Oporto, Portugal, 4Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, 5Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 6Public Health Institute of Oporto University, Oporto, Portugal

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In Osteoporosis, hip fractures account for significant disease burden, with increased morbi-mortality and financial load on the patient and healthcare system. This study aimed to assess cumulative survival rate of patients with hip fragility fracture aged >= 65 years old, referred to a Rheumatology Department’s Fracture Liaison Service (FLS) after admission to the Orthopaedics Inpatient Care Department, and to determine predictors of mortality.

Methods:

Longitudinal retrospective study of patients referred to a Rheumatology Departmenrt’s FLS from March 2015 until March 2017. Demographic and clinical data were collected. Statistical analysis was performed with STATA. Survival cumulative probabilities were calculated through Kaplan-Meyer curves and hazard ratios (HR) through cox regression, adjusted to age/degree of care dependency.

Results:

522 patients were referred to the FLS, 79.7% female, with median age of 84 years old (65-103). Table 1 summarizes clinical and demographic characteristics. One hundred and nineteen patients (22.8%) died, 36 still during inpatient care. The cumulative survival probability (image 1) at 1, 3, 6, 12 and 24 months was 94.1% (95%CI 91.7-95.9), 91.1% (95%CI 88.2-93.3), 86,3% (95%CI 82.9-89.0%), 81.7 (95%CI 77.9-84.8) and 73.8% (95%CI 69.2-77.8) respectively. Patients >=80 years old presented lower survival rate (HR 1.64, p=0.02), as well as partially dependent and totally dependent patients (HR 1.93, p=0.047; HR 5.3, p=0.000, respectively). Higher femur BMD (HR 0.01, p=0.023) and T-score (HR 0.67, p=0.038) were predictors of better survival outcome. Considering laboratory measurements, higher beta-crosslaps serum values predicted worse survival outcome (HR 4.27, p=0.007). Gender, fracture classification, type of surgical intervention, presence of vertebral fractures, BMI, serum vitamin D and osteocalcin didn’t have impact on survival.

Conclusion:

Knowledge of mortality predictors in hip fracture is essential to optimize survival in these patients. In our study, age, autonomy degree, femur BMD/T-score and beta-crosslaps had impact on survival outcome.

Table 1 – Clinical and demographic characteristics of sample

Total (N)

522

Age at admission, y (median, min-max)

84 (65-103)

Sex, female (n, %)

416, 79.7

Deaths (n, %)

During inpatient care (n, %)

119, 22.8

36, 6.9

BMI (N)

Underweight (n, %)

Normal (n, %)

Overweight (n, %)

Obesity class I (n, %)

218

80, 36.7

117, 53.7

20, 9.2

1, 0.5

Degree of care dependency (N)

Totally dependent (n,%)

Partially dependent (n,%)

Autonomous (n,%)

307

23, 7.5

78, 25.4

206, 67.1

Type of fracture

Transtrochanteric (n,%)

Femoral neck (n,%)

Subtrochanteric (n,%)

262, 50.2

221, 42.3

38, 7.3

Subsequent fracture (n,%)

47, 9.0%

Vertebral fracture (N)

0 (n,%)

1 fracture (n,%)

>= 2 fractures (n,%)

236

100, 42.4

56, 25.9

80, 33.9

Femur BMD, g/cm2 (median, min-max, N)

0.70, 0.36-1.18, 214

Femur T score (median, min-max, N)

>2.5 (n,%)

<=2.5 (n,%)

-2.6, -7.0-0.7, 214

87, 40.7

127, 59.3

Intervention (N)

Conservative (n,%)

Osteosynthesis (n,%)

Hemiarthroplasty (n,%)

Total arthroplasty (n,%)

Girdlestone (n,%)

516

11, 2.1

337, 65.3

87, 16.9

80, 15.5

1, 0.2

25(OH)D, ng/ml (median, min-max, N)

23, 3-54, 219

OC ng/ml (median, min-max, N)

28.2, 6.80-198.60, 215

Beta-crosslaps (median, min-max, N)

0.71, 0.12-3.28, 217

Image 1 – Cumulative survival probability of study sample


Disclosure: M. Guerra, None; S. Ganhão, None; F. Aguiar, None; G. Terroso, None; R. Vieira, None; D. Gonçalves, None; T. Meirinhos, None; T. Martins-Rocha, None; A. Águeda, None; R. Ferreira, None; M. Bernardes, Pfizer, Inc., 9,Lilly, 9,Janssen, 9,Merck & Co., 9,GlaxoSmithKline, 9; C. Vaz, None; R. Lucas, None; L. Costa, None.

To cite this abstract in AMA style:

Guerra M, Ganhão S, Aguiar F, Terroso G, Vieira R, Gonçalves D, Meirinhos T, Martins-Rocha T, Águeda A, Ferreira R, Bernardes M, Vaz C, Lucas R, Costa L. Predictors of Mortality in Patients with Hip Fragility Fracture [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/predictors-of-mortality-in-patients-with-hip-fragility-fracture/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-mortality-in-patients-with-hip-fragility-fracture/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology